April 25th 2025
Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.
Dr Mark Fendrick Testifies on Allowing VBID Flexibility in Medicare Advantage
June 7th 2017In testimony before the US House Ways and Means Committee’s Health subcommittee, Mark Fendrick, MD, co-director of the University of Michigan Center for Value-Based Insurance Design, discussed the importance of allowing for flexibility and clinical nuance when it comes to encouraging value in Medicare Advantage plans.
Read More
This Week in Managed Care: June 2, 2017
June 2nd 2017This week, the top managed care stories include an announcement that CMS will take Social Security numbers off Medicare cards; a national plan to combat chronic obstructive pulmonary disease was released; and a nutrition advocacy group calls on FDA to stick with the schedule for a new nutrition facts label.
Watch